Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas

19. Oktober 2017 aktualisiert von: Steven J. Russell, MD, PhD, Massachusetts General Hospital

The Summer Camp Study 2: Outpatient Automated Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas in a Pediatric Population Ages 6-11 at the Clara Barton Diabetes Camps

This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improve glycemic control vs. usual care for young people with type 1 diabetes ages 6-11 years old in a diabetes camp environment.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

19

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Vereinigte Staaten
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02114
        • Massachusetts General Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

6 Jahre bis 11 Jahre (Kind)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria

  • Age 6-11 years with type 1 diabetes for at least one year
  • Diabetes managed using an insulin infusion pump for ≥ three months
  • Willing to wear two infusion sets and continuous glucose monitoring (CGM) sensor and change sets frequently (at least one new glucagon infusion set daily)
  • Otherwise healthy (mild chronic disease such as asthma will be allowed if well controlled that do not require medications that result in exclusion)

Exclusion Criteria

  • Unable to provide informed consent, informed assent or parental consent
  • Unable to comply with study procedures
  • Current participation in another diabetes-related clinical trial that, in the judgment of the principal investigator, will compromise the results of this study or the safety of the subject
  • End stage renal disease on dialysis (hemodialysis or peritoneal dialysis)
  • Pregnancy (positive urine human chorionic gonadotropin [HCG])
  • History of liver disease that is expected to interfere with the anti-hypoglycemia action of glucagon (e.g. liver failure or cirrhosis). Other liver disease (i.e. active hepatitis, steatosis, active biliary disease, any tumor of the liver, hemochromatosis, glycogen storage disease) may exclude the subject if it causes significant compromise to liver function or may do so in an unpredictable fashion
  • Personal history of cystic fibrosis, pancreatitis, or other pancreatic disease, including pancreatic tumor or insulinoma
  • History of prolonged QT or arrhythmia, congenital heart disease or current known cardiac disease
  • Acute illness (other than non-vomiting viral illness) or exacerbation of chronic illness other than type 1 diabetes (T1D) at the time of the study
  • Seizure disorder, history of any seizure within the last two years, or ongoing treatment with anticonvulsants
  • Untreated or inadequately treated mental illness (indicators would include symptoms such as psychosis, hallucinations, mania, and any psychiatric hospitalization in the last year), or treatment with second generation anti-psychotic medications, which are known to affect glucose regulation.
  • Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be susceptible to radio-frequency (RF) interference
  • Use of oral (e.g. thiazolidinediones, biguanides, sulfonylureas, glitinides, dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose linked transporter 2 (SGLT-2) inhibitors) anti-diabetic medications
  • History of adverse reaction to glucagon (including allergy) besides nausea and vomiting.
  • Unwilling or unable to completely avoid acetaminophen during the comparator and bionic pancreas arms of the study
  • History of eating disorder such as anorexia, bulimia, or diabulemia or omission of insulin to manipulate weight
  • History of intentional, inappropriate administration of insulin leading to severe hypoglycemia requiring treatment
  • Any factors that, in the opinion of the principal investigator, would interfere with the safe completion of the study procedures

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Crossover-Aufgabe
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Bionic Pancreas
Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 5 days.
Gerät: Bionic Pancreas
Automated blood glucose control via a closed-loop bionic pancreas device.
Andere Namen:
  • Bionische Bauchspeicheldrüse der Boston University
Experimental: Usual Care
Usual Care diabetes management in a diabetes camp environment including a nurse or nursing student assigned to each cabin and review and adjustment of the insulin regimen daily by a physician or nurse practitioner, all participants using the participant's own insulin pump and a continuous glucose monitor if they use one as part of their usual care, for 5 days.
Sonstiges: Usual Care
As a comparator control, usual diabetes camp care with the participant's own insulin pump.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Mean Continuous Glucose Monitoring Glucose (CGMG) Values During Days 2 to 5
Zeitfenster: Days 2 to 5 of each period
Glucose reading were taken every 5 minutes by the CGM. The CGM glucose results during Days 2 through 5 were averaged.
Days 2 to 5 of each period
Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 5
Zeitfenster: Days 2 to 5 of each period
Glucose reading were taken every 5 minutes by the CGM. The percentage of time that the glucose concentration was less than 60 mg/dL [3.3 millimoles/liter (mmol/L)] during Days 2 through 5 was calculated.
Days 2 to 5 of each period

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Mean CGMG Values
Zeitfenster: Day 1 and Days 1-5 in each period
Glucose reading were taken every 5 minutes by the CGM. The glucose results for each time frame were averaged.
Day 1 and Days 1-5 in each period
Percentage of Time With CGMG Concentration by Ranges During Day 1
Zeitfenster: Day 1 of each period
Glucose readings were taken every 5 minutes by the CGM. The percentage of time that the glucose concentration was less than the following ranges were calculated: < 50 mg/dL(2.8 mmol/L), < 70 mg/dL (3.9 mmol/L), 70-180 mg/dL (3.9 to 10.0 mmol/L), > 180 mg/dL (10.0 mmol/L).
Day 1 of each period
Percentage of Time With CGMG Concentration by Ranges During Days 1 to 5
Zeitfenster: Days 1 to 5 of each period
Glucose readings were taken every 5 minutes by the CGM. The percentage of time that the glucose concentration was less than the following ranges were calculated: < 50 mg/dl (2.8 mmol/L), < 70 mg/dl (3.9 mmol/L), 70-180 mg/dl (3.9 to 10.0 mmol/L), > 180 mg/dL (10.0 mmol/L).
Days 1 to 5 of each period
Percentage of Time With CGMG Concentration by Ranges During Days 2 to 5
Zeitfenster: Days 2 to 5 of each period
Glucose readings were taken every 5 minutes by the CGM. The percentage of time that the glucose concentration was less than the following ranges were calculated: < 50 mg/dl (2.8 mmol/L), < 70 mg/dl (3.9 mmol/L), 70-180 mg/dl (3.9 to 10.0 mmol/L), > 180 mg/dL (10.0 mmol/L).
Days 2 to 5 of each period
Percentage of Participants With Mean CGMG Glucose <154 mg/dL
Zeitfenster: Day 1, Days 1-5, and Days 2-5 of each period
Glucose reading were taken every 5 minutes by the CGM. The glucose readings were averaged. 154 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 7.0%.
Day 1, Days 1-5, and Days 2-5 of each period
Percentage of Participants With Mean CGMG Glucose <169 mg/dL
Zeitfenster: Day 1, Days 1-5, and Days 2-5 of each period
Glucose reading were taken every 5 minutes by the CGM. The glucose readings were averaged. 169 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 7.5%.
Day 1, Days 1-5, and Days 2-5 of each period
Percentage of Participants With Mean CGMG Glucose <183 mg/dL
Zeitfenster: Day 1, Days 1-5, and Days 2-5 of each period
Glucose reading were taken every 5 minutes by the CGM. The glucose readings were averaged. 183 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 8.0%.
Day 1, Days 1-5, and Days 2-5 of each period
Number of CGMG Reported Hypoglycemic Events (< 70 mg/dL, < 60 mg/dL, <50 mg/dL)
Zeitfenster: Days 1-5
A series of hypoglycemic measurements is defined as a single event until there is a break of ≥ 30 minutes between measurements below the defined thresholds of < 70, < 60, and <50 mg/dL.
Days 1-5
Mean Plasma Glucose Values
Zeitfenster: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The plasma glucose readings were averaged. The plasma glucose results on Day 1, Days 1 to 5 and Days 2 to 5 were averaged.
Day 1, Days 1 to 5, and Days 2 to 5 of each period
Percentage of Time With Plasma Glucose Values by Ranges on Day 1
Zeitfenster: Day 1 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The percentage of time that the plasma glucose concentration was less than the following ranges were calculated: < 70 mg/dl (3.9 mmol/L), < 60 mg/dL (3.3 mmol/L), < 50 mg/dl (2.8 mmol/L).
Day 1 of each period
Percentage of Time With Plasma Glucose Values by Ranges on Days 1 to 5
Zeitfenster: Days 1 to 5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The percentage of time that the plasma glucose concentration was less than the following ranges were calculated: < 70 mg/dL (3.9 mmol/L), < 60 mg/dL (3.3 mmol/L), < 50 mg/dL (2.8 mmol/L).
Days 1 to 5 of each period
Percentage of Time With Plasma Glucose Values by Ranges on Days 2 to 5
Zeitfenster: Days 2 to 5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The percentage of time that the plasma glucose concentration was less than the following ranges were calculated: < 70 mg/dl (3.9 mmol/L), < 60 mg/dL (3.3 mmol/L), < 50 mg/dl (2.8 mmol/L).
Days 2 to 5 of each period
Percentage of Participants With Mean Plasma Glucose <154 mg/dL
Zeitfenster: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The plasma glucose readings were averaged. 154 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 7.0%.
Day 1, Days 1 to 5, and Days 2 to 5 of each period
Percentage of Participants With Mean Plasma Glucose <169 mg/dL
Zeitfenster: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The plasma glucose readings were averaged. 169 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 7.5%.
Day 1, Days 1 to 5, and Days 2 to 5 of each period
Percentage of Participants With Mean Plasma Glucose <183 mg/dL
Zeitfenster: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The plasma glucose readings were averaged. 183 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 8.0%.
Day 1, Days 1 to 5, and Days 2 to 5 of each period
Number of Plasma Glucose Reported Hypoglycemic Events (< 70 mg/dL, < 60 mg/dL, <50 mg/dL)
Zeitfenster: Days 1-5
A series of hypoglycemic measurements is defined as a single event until there is a break of ≥ 30 minutes between measurements below the defined thresholds of < 70, < 60, and <50 mg/dL.
Days 1-5
Percentage of Days That CGM Data Was Used by Participants as Part of Their Usual Care
Zeitfenster: Day 1, Days 1-5, and Days 2-5 of the Usual Care Period
The percentage of days during the Usual Care period that participants used CGM data as part of their diabetes management.
Day 1, Days 1-5, and Days 2-5 of the Usual Care Period
Number of Carbohydrate Interventions for Hypoglycemia When Plasma Glucose <70 mg/dL
Zeitfenster: Day 1, Days 1-5, and Days 2-5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). Participants were given 15 grams (g) of simple carbohydrates if their plasma glucose concentration dropped below 4.4 mmol/L. These simple carbohydrates were counted as interventions for study outcomes if the plasma glucose concentration was less than 3.9 mmol/L. A second intervention of 15 g of carbohydrate was given if a repeat measurement in 15-20 min was less than 3.9 mmol/L. The total number of carbohydrate interventions are reported.
Day 1, Days 1-5, and Days 2-5 of each period
Grams of Carbohydrate Taken for Hypoglycemia When Plasma Glucose <70 mg/dL
Zeitfenster: Day 1, Days 1-5, and Days 2-5 of each period
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). Participants were given 15 grams (g) of simple carbohydrates if their plasma glucose concentration dropped below 4.4 mmol/L. These simple carbohydrates were counted as interventions for study outcomes if the plasma glucose concentration was less than 3.9 mmol/L. A second intervention of 15 g of carbohydrate was given if a repeat measurement in 15-20 min was less than 3.9 mmol/L.
Day 1, Days 1-5, and Days 2-5 of each period
Insulin Total Daily Dose
Zeitfenster: 11 days
Insulin total daily dose is reported in units per kilogram per day (U/kg/day).
11 days
Glucagon Total Daily Dose Levels in the Bionic Pancreas Arm
Zeitfenster: Day 1, Days 1-5, and Days 2-5 of each period
Glucagon dose level is reported in micrograms per kilogram of body mass per day (µg/kg/day).
Day 1, Days 1-5, and Days 2-5 of each period
Daily Basal Insulin Dose in the Bionic Pancreas Period
Zeitfenster: Day 1 through Day 5
The bionic pancreas automatically adapted insulin dosing to each individual's needs. When CGM data were not available (because of sensor failure or during the warm-up time after sensor replacement), the bionic pancreas automatically delivered a dose of basal insulin based on the mean basal dosing it had calculated at that time on previous days. Daily basal insulin dose is reported in units per kilogram (kg) per day (U/kg).
Day 1 through Day 5
Daily Bolus Insulin Dose in the Bionic Pancreas Period
Zeitfenster: Day 1 through Day 5
The first time the bionic pancreas was used in each participant, a partial meal-priming bolus based on the participant's body mass (0.05 units/kg) was delivered. After the first use, the size of the meal-priming bolus was adapted by the bionic pancreas to 75% of the 4-hour prandial insulin used for that meal type and size. Daily bolus insulin dose is reported in units per kilogram (kg) per day (U/kg).
Day 1 through Day 5
Carbohydrate Intake
Zeitfenster: Day 1, Days 1-5 and Days 2-5
Carbohydrate intake included meals, snacks and unscheduled carbohydrates administered when a participant's blood glucose was <80 mg/dl (or for symptoms at any glucose level). Carbohydrate intake per day was averaged and is reported in grams (g) per kilogram (kg) per day (g/kg/day).
Day 1, Days 1-5 and Days 2-5
Number of Unscheduled Infusion Set Changes
Zeitfenster: Day 1
Infusion sets for administering insulin and glucagon were placed under the skin the in the abdomen, buttocks, arms, or legs. Infusion set changes due to pain, infusion set falling out or infusion set failure are reported. Camp policy was to suspect failure of the infusion set whenever ketonemia occurred, so failures may not have actually been set failures, but rather failure to deliver enough insulin.
Day 1
Number of Unscheduled Infusion Set Changes
Zeitfenster: Days 1-5
Infusion sets for administering insulin and glucagon were placed under the skin the in the abdomen, buttocks, arms, or legs. Infusion set changes due to pain, infusion set falling out or infusion set failure are reported. Camp policy was to suspect failure of the infusion set whenever ketonemia occurred, so failures may not have actually been set failures, but rather failure to deliver enough insulin.
Days 1-5
Number of Unscheduled Infusion Set Changes
Zeitfenster: Days 2-5
Infusion sets for administering insulin and glucagon were placed under the skin the in the abdomen, buttocks, arms, or legs. Infusion set changes due to pain, infusion set falling out or infusion set failure are reported. Camp policy was to suspect failure of the infusion set whenever ketonemia occurred, so failures may not have actually been set failures, but rather failure to deliver enough insulin.
Days 2-5
Number of Bionic Pancreas Local Infusion Site Reactions
Zeitfenster: Day 1, Days 1-5 and Days 2-5
Local infusion site reactions are defined as pain at the infusion site of the Bionic Pancreas. Itching and redness may have also been present.
Day 1, Days 1-5 and Days 2-5
Mean Nausea Index Score Using a Visual Analogue Scale (VAS)
Zeitfenster: Day 1, Days 1-5, and Days 2-5 in each period
Participants rated their nausea using a 0 to 10 centimeter (cm) VAS where 0=least severe nausea to 10=most severe nausea. The average nausea index scores from Day 1 to Day 5 were calculated
Day 1, Days 1-5, and Days 2-5 in each period
Number of Severe Hypoglycemic Events
Zeitfenster: Day 1, Days 1-5 and Days 2-5
A severe hypoglycemic event is an event where the participant is unable to self-treat and requires the assistance of another person.
Day 1, Days 1-5 and Days 2-5
Percentage of Time Participants Were Not Under Bionic Pancreas Control During the Bionic Pancreas Period
Zeitfenster: 5 days
Percentage of time that the Bionic pancreas was not functioning properly due to loss of wireless connectivity.
5 days
Percentage of Time Without CGM Monitoring Data
Zeitfenster: 5 days
Percentage of time without CGM monitoring data is the time when the participant's CGM device lost its CGM signal.
5 days
Change From Baseline in Body Weight
Zeitfenster: 5 days
The change in body weight collected at Day 5 of each period relative to Baseline. A negative change from Baseline indicates a reduction in body weight and a positive change from Baseline indicates an increase in body weight.
5 days
Reliability Index
Zeitfenster: Day 1, Days 1-5, and Days 2-5 in each period
Reliability index was calculated as the percentage of time values were actually recorded by CGM.
Day 1, Days 1-5, and Days 2-5 in each period
List of Technical Faults Associated With the Bionic Pancreas Including Cause and Resolution
Zeitfenster: 5 days
5 days
Number of Unscheduled CGM Sensor Changes
Zeitfenster: 5 days
The number of time a CGM sensor was replaced due to falling out or failing to report a glucose value.
5 days
Percentage of Participants Using a Glucagon-Like Peptide-1 (GLP-1) Agonist During the Usual Care Period
Zeitfenster: 5 days
The percentage of participants who used a GLP-1 agonist to manage their diabetes during the Usual Care period.
5 days
Percentage of Participants Using Pramlintide During the Usual Care Period
Zeitfenster: 5 days
The percentage of participants who used pramlintide to manage their diabetes during the Usual Care period.
5 days

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Massachusetts General Hospital

Mitarbeiter

Boston University

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Nützliche Links

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Juni 2014

Primärer Abschluss (Tatsächlich)

1. August 2014

Studienabschluss (Tatsächlich)

1. August 2014

Studienanmeldedaten

Zuerst eingereicht

2. April 2014

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. April 2014

Zuerst gepostet (Schätzen)

7. April 2014

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. Oktober 2017

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

19. Oktober 2017

Zuletzt verifiziert

1. Oktober 2017

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 2014P000630

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Diabetes Typ 1

Klinische Studien zur Bionic Pancreas

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Tunisia

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

3
Abonnieren